1-(2,6-dichlorophenyl)-5-(2-naphthylmethyl)piperidin-2-one | 533910-16-6

• 分子结构分类: 有机化合物
• 英文名称: 1-(2,6-dichlorophenyl)-5-(2-naphthylmethyl)piperidin-2-one
• 英文别名: 1-(2,6-Dichlorophenyl)-5-(naphthalen-2-ylmethyl)piperidin-2-one
• CAS: 533910-16-6
• 化学式: C₂₂H₁₉Cl₂NO
• 分子量: 384.305
• InChiKey: QHTLGLGPSNMDHY-UHFFFAOYSA-N

物化性质

• 沸点：
  590.3±40.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1447401A1

  公开（公告）日：2004-08-18

  A piperidin-2-one derivative compound represented by formula (I): wherein all symbols are described in the specification, or a non-toxic salt thereof. The compound represented by formula (I) inhibits activation of p38MAP kinase, and is useful for prevention and/or treatment of various inflammatory diseases, rheumatoid arthritis, osteoarthritis, arthritis, osteoporosis, autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, atrial myxoma, psoriasis, dermatitis, gout, adult respiratory distress syndrome (ARDS), arteriosclerosis, post-percutaneous transluminal coronary angioplasty (PTCA) restenosis or pancreatitis.

  一个由公式(I)表示的哌啶-2-酮衍生物化合物： 其中所有符号都在说明书中描述，或其无毒盐。 由公式(I)表示的化合物能抑制p38MAP激酶的激活，并且可用于预防或治疗各种炎症性疾病、类风湿性关节炎、骨关节炎、关节炎、骨质疏松症、自身免疫病、感染性疾病、败血症、恶病质、脑梗塞、阿尔茨海默病、哮喘、慢性肺泡炎、再灌注损伤、血栓形成、肾小球肾炎、糖尿病、移植物抗宿主病、炎症性肠病、克罗恩病、溃疡性结肠炎、多发性硬化症、肿瘤生长和转移、多发性骨髓瘤、浆细胞白血病、卡斯尔曼病、心房粘液瘤、银屑病、皮炎、痛风、成人呼吸窘迫综合征（ARDS）、动脉硬化、经皮腔内冠状动脉成形术（PTCA）后再狭窄或胰腺炎。
• Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
  申请人：Takahashi Kanji

  公开号：US20050085509A1

  公开（公告）日：2005-04-21

  A piperidin-2-one derivative compound represented by formula (I): wherein all symbols are described in the specification, or a non-toxic salt thereof. The compound represented by formula (I) inhibits activation of p38MAP kinase, and is useful for prevention and/or treatment of various inflammatory diseases, rheumatoid arthritis, osteoarthritis, arthritis, osteoporosis, autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, atrial myxoma, psoriasis, dermatitis, gout, adult respiratory distress syndrome (ARDS), arteriosclerosis, post-percutaneous transluminal coronary angioplasty (PTCA) restenosis or pancreatitis.

  一种由式（I）所代表的哌啶-2-酮衍生物化合物，其中所有符号均在规范中描述，或其非毒性盐。该式（I）所代表的化合物抑制p38MAP激酶的活化，可用于预防和/或治疗各种炎症性疾病，风湿性关节炎，骨关节炎，关节炎，骨质疏松症，自身免疫性疾病，感染性疾病，败血症，消瘦症，脑梗塞，阿尔茨海默病，哮喘，慢性肺炎性疾病，再灌注损伤，血栓形成，肾小球肾炎，糖尿病，移植物抗宿主排斥，炎症性肠病，克罗恩病，溃疡性结肠炎，多发性硬化症，肿瘤生长和转移，多发性骨髓瘤，浆细胞白血病，卡斯尔曼病，心房黏液瘤，牛皮癣，皮炎，痛风，成人呼吸窘迫综合征（ARDS），动脉硬化，经皮冠状动脉成形术（PTCA）再狭窄或胰腺炎。